Comparison of GW433908 and Nelfinavir in HIV Patients Who Have Not Had Antiretroviral Therapy
HIV Infections
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring HIV-1, Drug Therapy, Combination, HIV Protease Inhibitors, Lamivudine, Nelfinavir, Reverse Transcriptase Inhibitors, Anti-HIV Agents, abacavir
Eligibility Criteria
Inclusion Criteria Patients may be eligible for this study if they: Are at least 13 years old (consent of parent or guardian required if under 18). Agree to use a proven barrier method of birth control (e.g., spermicide plus condom) during the study period (hormonal birth control will not be accepted), if able to have children. Have received less than 4 weeks treatment with any nucleoside reverse transcriptase inhibitor (NRTI) and have never received any nonnucleoside reverse transcriptase inhibitor (NNRT) or protease inhibitor (PI). Have a viral load (amount of HIV in the blood) of 5,000 copies/ml or more, or have a positive result at the screening visit. Exclusion Criteria Patients will not be eligible for this study if they: Abuse drugs or alcohol in a way that would interfere with the study, in the opinion of the doctor. Patients stable on methadone will be considered for participation. Have an active/acute CDC Category C event. Are unable to absorb or take medicines by mouth. Are pregnant or breast-feeding. Have a serious medical condition (such as diabetes, heart problem, hepatitis) that might affect the safety of the patient. Have had pancreatitis or hepatitis within the last 6 months. Have been treated with radiation or chemotherapy within 28 days before the study drug will be taken, or will have the need for these during the study. Have taken drugs that affect the immune system (such as corticosteroids, interleukins, interferons) or that have anti-HIV activity (such as hydroxyurea or foscarnet) within 28 days before the study drug will be taken. Have received HIV vaccine within 3 months before the study drug will be taken. Have received certain other drugs within 28 days before the study drug will be taken, or think that they will be needed during the study. Have received experimental treatments. Have allergies which might interfere with the study, in the opinion of the doctor.
Sites / Locations
- East Bay Clinical Trial Ctr
- Ocean View Internal Medicine
- Florida ID Group
- Hillsborough County Health Dept
- Clinical Pharmacology Services
- Veterans Affairs Med Ctr of North Chicago
- Univ of Kansas Med Ctr
- Saint Michael's Med Ctr
- UMDNJ - New Jersey Med School
- Bronx Municipal Hosp Ctr/Jacobi Med Ctr
- Addiction Research and Treatment Corp
- Brookdale Univ Hosp and Med Ctr
- Gervais Frechette
- Howard Grossman
- Mount Sinai School of Medicine
- Univ of Rochester Med Ctr
- SMO-USA Inc
- Advanced Clinical Trials Inc
- Thomas Jefferson Univ
- Univ of Texas Med Branch
- MacGregor Med Association
- Walter Gaman
- Southwest Texas Methodist Hosp